Skip To Main Content
Jason Pontin on Muck Rack

Jason Pontin

Palo Alto
As seen in: Medium, The New York Times, Forbes, HuffPost, CNBC, TED, WIRED Magazine, MIT Technology Review, The Boston Globe, The Information and
General Partner @DCVC. Cofounder @totustx. Chair @zwitterco+@KanvasBio. Board @ProximaBio+@DayhoffLabs+@RelationRx+@recycleye. Formerly, EIC+CEO @techreview
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

DCVC 2026 Q 1 update

|
By Jason Pontin, Matthew Ocko, James Hardiman
| DCVC
Friends of DCVC, Our portfolio companies had a busy quarter attracting major new funding (about $2 billion in aggregate), securing key commercial partnerships, and scaling fundamental technologies needed to accelerate AI, defense, energy, quantum, agriculture, medicine, and more. Behind each piece of news below is dazzling technology spun from a flywheel of proprietary data, deep compute, and insight derived from a given product’s contact with the real world.
Open in Who Shared Issue with article?

Deep Tech Opportunity: TechBio companies are using data to rethink…

|
By Jason Pontin, James Hardiman, Zachary Bogue
| DCVC
Last year’s edition of the DCVC Deep Tech Opportunities Report, released in June 2025, explains the global challenges we see as the most critical and the possible solutions we hope to advance through our investing. This is a condensed and updated version of the report’s fifth chapter.
Open in Who Shared Issue with article?

Proxima raises $80M in seed financing, led by DCVC, to reprogram…

|
By Jason Pontin, James Hardiman, Zachary Bogue
| DCVC
Proteins, carriers of the signals that can spark or stop cellular functions, seldom work alone — they’re found in complexes with other proteins. Among drug hunters there’s been a growing hope that if we could understand, control, and disrupt how proteins lock together, it might give us new ways to slow difficult-to-treat diseases like cancer or autoimmune disorders.
Open in Who Shared Issue with article?
See all 189 licensed articles (193 Total)